The combination therapy of agonistic anti-CD40 monoclonal antibody and CSF-1R inhibitor effectively inhibits tumor growth in mouse models of melanoma by targeting TAMs, transforming “cold” into “inflamed” tumor microenvironment [215]. Here, CSF1R is linked to melanoma.